Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Micardis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Micardis was produced by Boehringer Ingelheim and Astellas.

Boehringer Ingelheim returns to growth after US turnaround

Boehringer Ingelheim returns to growth after US turnaround

Boehringer's heart drug Micardis (telmisartan) continued to suffer the effects of generic competition, with sales down 12.1% to 956m, but 2015 also saw the company's diabetes portfolio making

Humira remains top pharma product, but Sovaldi closes in

Humira remains top pharma product, but Sovaldi closes in Boehringer has seen a similar situation with its heart drug Micardis(telmisartan) that has been losing patent protection for over a year.

Heart drug sales continue downward spiral

Heart drug sales continue downward spiral Finally Boehringer, which saw the largest drop in the top ten table due predominately to the patent loss of Micardis (telmisartan).

Boehringer's sales drop after 'intense and challenging' year

Boehringer's sales drop after 'intense and challenging' year During the year all four of Boehringer's top products saw their global sales decline, most noticeably cardiovascular drug Micardis (telmisartan) and COPD treatment Combivent (ipratropium and albuterol), both of which

Micardis

Micardis campaign. Created by Seven Stones for Boehringer Ingelheim. Therapy area: Cardiovascular

1 2 3 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics